Navigation Links
Enobia Pharma Raises $40.1 Million Series B Financing
Date:9/11/2007

MONTREAL and QUEBEC, Sept. 11 /PRNewswire/ -- Enobia Pharma Inc, announced today that it raised $Cdn 40.1 Million in a Series B multi-tranche financing. The proceeds will be used primarily to fund the Company's novel hypophosphatasia drug development program through Phase 2 clinical trials. There is no known cure for hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.

The financing was co-led by new investors OrbiMed Advisors LLC ("OrbiMed") of New York and CTI Life Sciences Fund of Montreal ("CTI"). The Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000, current investors in the Company, also participated in the round.

Robert Heft, PhD, President and CEO of Enobia said, "With no drug therapy available, hypophosphatasia patients and their families experience prolonged and significant suffering. We are pleased that we were able to attract such world class investors to our company at this important time in our development. We are confident that with their support, we will build on our promising preclinical results to advance the clinical development program of an enzyme replacement therapy for hypophosphatasia."

Jonathan Silverstein, General Partner of OrbiMed said, "We are delighted to be associated with this impressive team working on such a debilitating disease for which there is no cure."

Richard Meadows, Managing Partner of CTI said, "This represents an example of the type of high quality investment opportunity that exists in Quebec and that is capable of attracting the attention and significant investment from our U.S. VC colleagues."

Both Mr. Silverstein and Mr. Meadows will join the newly constituted Board, which also includes: Robert Heft, who previously served on the Board; Fredric Price, also a former Board member, and an investor in this Series B financing who was previously Chairman & CEO of BioMarin Pharmaceutical and Thomas Schuetz, MD, PhD, wh
'/>"/>

SOURCE Enobia Pharma Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... CSM, a leading clinical trial supply company, today announced that Michael ... extensive background in financial management and accounting, bringing over 20 years of experience in ... will oversee all financial areas of the company to both strengthen CSM’s financial strategy ...
(Date:7/6/2015)... ... July 06, 2015 , ... A study ... insights into how virulent fungi adapt through genetic modifications to fight back against ... leaves them temporarily weakened. These insights may provide clues to new ways to ...
(Date:7/6/2015)... Wellesley, Mass. (PRWEB) , ... July 06, 2015 ... ... development of simpler and cheaper molecular diagnostic tests are key drivers of the ... projected growth of personalized medicine and the introduction of new companion diagnostic tests ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... on a poultry farm in Texas. Soon, there are reports ... and New Jersey. How can health officials be mobilized to ... humans? , ,That process may well begin at the All-Emergency ... Services Secretary Tommy Thompson to keep tabs on the range ...
... , today announced the addition of two new members ... Weis. , ,The Madison-based media communications company hopes to ... its board of directors with the appointments. Peercy and ... meeting, at which time they will stand for election. ...
... intranets are frustrated. In a recent Moreover survey, 58 ... information resource at work, but only 11 percent considered ... Given all the money and effort that has gone ... value in them? , ,By 1998, companies were already ...
Cached Biology Technology:Federal command center is at the front line of defense for public health emergencies 2Federal command center is at the front line of defense for public health emergencies 3The unfilled promise of corporate intranets 2The unfilled promise of corporate intranets 3
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
(Date:6/10/2015)... 10, 2015 According to ... by Technology (Ultrasound, TOF, Structured Light, Stereo Vision), ... Automotive) and by Geography - Trends & Forecast ... market is expected to reach $3,319.71 Million by ... 2015 and 2020. Browse 71 market ...
(Date:6/9/2015)... DUBLIN , June 09, 2015 ... the addition of the "Gesture Recognition & ... Application (Consumer Electronics, Automotive, & Others), Product (Biometric ... Forecast to 2020" report to their offering. ... sensing market is expected to reach $ 23.55 ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... of folic acid around the time of conception and throughout ... one day deserve a spot on the obstetrician,s list of ... choline a nutrient found in eggs and meat ... such as mental health disturbances, and chronic conditions, like hypertension, ...
... floating islands containing papyrus plants to help protect the ... Kenya. The German REWE Group is funding a ... grower Finlays and Dr David Harper, a Senior Lecturer ... the water-cleansing services of papyrus as artificial floating islands. ...
... Sept. 20, 2012 Novetta Solutions, LLC (Novetta), ... announced the acquisition of International Biometric Group, LLC ... to customers within the National Security community and ... Novetta was established in March 2012 through the ...
Cached Biology News:Nutrient in eggs and meat may influence gene expression from infancy to adulthood 2Nutrient in eggs and meat may influence gene expression from infancy to adulthood 3Novel plastic-and-papyrus restoration project 2Novel plastic-and-papyrus restoration project 3Novetta Solutions Acquires International Biometric Group, LLC 2Novetta Solutions Acquires International Biometric Group, LLC 3
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human Legumain Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: